Business news

    ResMed (ASX:RMD) records 12% revenue growth in Q2 FY24, reaching $1.16B

    Article Image

    ResMed reported $1.16 billion in revenue for the second quarter of FY24, a 12% increase from the same period the previous year.

    The growth was attributed to strong performance across the company's device, masks, accessories, and residential care software businesses.

    Net income for the period decreased by 7% to $208.8 million, while non-GAAP net income rose by 13% to $277.3 million.

    The company's gross margin was slightly down from the previous year at 55.6%. The company aims to improve the lives of 250 million people by 2025 through its expansion in the sleep and breathing health markets.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa